Enhanced Predictability and Reliability in DVT Clot Management
By MedTech Outlook | Monday, March 18, 2019
Vetex Thrombectomy Catheter is the first option for interventional treatment to increase predictability and reliability in DVT Clot Management. Vetex was designed in order to provide a more efficient solution in one session to clinicians without the use of thrombolytic agents by removing large quantities of the clot. This will reduce the ICU and associated cost requirements. For interventional radiologists and vascular surgeons, it is an option of the first choice. VETEX Medical is an Irish medical device company that develops a revolutionary catheter for thrombectomy to quickly extract thrombus from patients who have venous thromboembolism in one single session.
Although anticoagulation is still the most common therapy for DVT, interventional treatment has shown the potential for better results in certain patients. Present interventional DVT treatments include the use, with or without mechanical devices, of thrombolytic drugs to dissolve the clot, or of purely mechanical equipment using fragmentation to form a core through the clot. Since thrombolytic agents thin the blood, many patients are at risk for bleeding, and prolonged hospital stays can be needed. In two years, up to 50 percent of patients with symptomatic DVT develop post-thrombotic syndrome, which involves chronic limb pain, swelling, heaviness, fatigue, and ulceration in the extremities.
As a platform for the venous vascular system, Vetex Medical has developed the Vetex thrombectomy catheter. It is targeted at a $1.7 billion mark with a 5.95 percent CAGR, deep- vein thrombosis (DVT), AV-Fistula, and pulmonary embolism (PE). Vetex Medical is initially targeting patients in iliofemoral veins with acute DVT. Vetex Medical has patent filings with international preliminary examination reports, and the freedom for third parties to conduct an evaluation. The market for venous thrombectomy has been unserved for several years but is now one of the key drivers of the market for clot management as clinical data and awareness increases.
Check this out: Top Biotechnology Companies
In the VETEX trial, a multicenter VetexTM thrombectomy catheter study, VeteXTM Medical Ltd has announced its initial treatment. Two minimally invasive technologies—a screw inside a basket—are combined with Vetex Thrombo-Catheter to easily and efficiently remove a large amount of wall-adherent coagulation without thrombolytic drugs. The non-randomized VETEX trial consists of a feasibility study of 30 patients treated with the Vetex device for acute iliofemoral DVT, the first outcome being a procedural success, defined as Grade II SIR Lysis with no adverse events associated with the procedure.